Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06503679 · ClinicalTrials.gov registry record · Phase 1
A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
A Phase 1 study, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT06503679 is a Phase 1 study that has completed, run by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. The registered enrollment target is 49 participants.
The verdict
NCT06503679, a Phase 1 study, has completed, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety and tolerability and pharmacokinetics of LY4100511 (DC-853) when administered alone or in the presence of cytochrome P450 substrates in healthy participants.
Interventions
- DRUG Midazolam
- DRUG Repaglinide
- DRUG LY4100511 (DC-853) Dose 1
- DRUG LY4100511 (DC-853) Dose 2
- DRUG LY4100511 (DC-853) Dose 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2024-07-16 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06503679
The ClinicalTrials.gov registry entry for NCT06503679 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Midazolam is the first listed.
NCT06503679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06503679 about?
NCT06503679 is a clinical study titled "A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants". The main purpose of this study is to assess the safety and tolerability and pharmacokinetics of LY4100511 (DC-853) when administered alone or in the presence of cytochrome P450 substrates in healthy participants.
What is the current status of trial NCT06503679?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2024-07-16. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT06503679?
The interventions under investigation include: Midazolam (DRUG), Repaglinide (DRUG), LY4100511 (DC-853) Dose 1 (DRUG), LY4100511 (DC-853) Dose 2 (DRUG), LY4100511 (DC-853) Dose 3 (DRUG).
Who is sponsoring clinical trial NCT06503679?
This trial is sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.